Elias Dakwar, MD

Present

RO1-AA058482-01 9/1/19 –

Grant funding recipient

NIAAA

Funding for “The role of brief potent glutamatergic modulation in addressing problem drinking: a randomized, controlled trial.”

Role: Principal Investigator

1R01-DA042070-01A1

Grant funding recipient 9/1/17 –

Funding for “Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled trial.”

Role: Principal Investigator

Past

U01-DA040647-01A1

Grant funding recipient 5/15/17 – 5/30/24

NIDA

Funding for “Pharmacological Facilitation of Behavioral Modification for Cocaine Use Disorders."

Role: Principal Investigator

1R21-AA023010

Grant funding recipient 7/1/14 – 6/30/17

NIAAA

Funding for "Brief Potent Glutamatergic Modulation to Address Alcohol Use Disorder"

Role: Principal Investigator

1R21-DA035472

Grant funding recipient 5/1/13 – 4/30/15

NIDA

Funding for “The effect of glutamatergic modulation on cocaine self-administration.”

Role: Principal Investigator

1K23-DA031771-06

Grant Funding Recipient 9/30/11 – 10/1/17

NIDA

Funding for “Brief Potent Glutamatergic Modulation: Applications for Cocaine Dependence.”

The purpose of this K23 is to integrate laboratory and clinical trials research with the candidate’s interest in developing innovative treatments for substance use disorders.

Role: Principal Investigator

P50-DA009236-17 (Kleber)

Pilot Funding Recipient 4/01/09 – 08/10/10

NIDA

Funding for “The effects of mindfulness-based meditation on cocaine and/or cannabis dependence.”

Role: Principal Investigator